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The Question of FK 506 Nephrotoxicity After Liver Transplantation 
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WE HAVE previously described the nephrotoxic qualities of FK 506,1-4 which were particularly 
evident in liver transplant recipients switched to FK 506 
after previous treatment with cyclosporine (CyA).1.2 The 
probability that these two drugs are synergistically neph-
rotoxic has precluded their use together,l a decision that 
has support from studies in a rat model of renal ischemia. 5 
However, FK 506 also can be nephrotoxic when given 
from the outset after transplantation. 3 Since the magnitude 
of drug nephrotoxicity is difficult to assess after renal 
transplantation, we have studied instead the postoperative 
renal function in cohorts of primary liver and thoracic 
organ recipients. This approach of investigating renal 
function in nonrenal organ recipients was used during the 
last decade to define the nephrotoxic liability of Cy A. 6-8 
CASE MATERIAl 
ThoraciC Organ Transplantation 
The patients, who were recently reported by Armitage et al,3 
received the following transplants: 22 hearts. 2 double lungs. and 
one heart·lung. The transplantations were performed between 
October 1989 and May 1990. Only two patients (both heart 
recipients) were eliminated from this analysis. One. an adult. died 
3.5 days postoperatively from right ventricular failure. The other. 
a 22-day-old infant who survived. had acute renal failure 3 weeks 
postoperatively at the same time as total thrombosis of the 
abdominal inferior vena cava up to retrohepatic levels occurred; 
the kidneys eventually recovered completely with the develop-
ment of venous collaterals. The clinical features of the 25 analyzed 
patients are summarized in Table I. There were four infants or 
children and 20 adults. 
Liver Transplantation 
The 120 patients who were recently reported by Todo et al9 
underwent primary liver replacement between September 8. 1989 
and February 4,1990. Of the starting group. 112 (93.3%) are alive 
with follow-ups of 6 to almost 12 months. Of the 112 survivors. 8 
have required retransplantation. These patients were eliminated 
from the analysis because of the complexity of their courses and 
the nearly invariable need for prolonged intensive care and 
nephrotoxic antibiotics. These factors and the rest of the spectrum 
of potential renal insults under conventional CyA immunosup-
Table 1. Thoracic Transplants Under FK 506 
Sex (21 M/4 F) 
Age range (22 d-54 y) 
Causes of heart failure 
Ischemic (10) 
Idiopathic (7) 
Congenital (5) 
Valvular (2) 
Circulatory support: 8 
Adapted lrom ArmiIage eI aI.3 
Table 2. Uver Transplant Patients Under FK 506 
Sex (58 M47 F) 
Age (mean) (45 ± 11.5 y) 
Causes of liver failure 
Adults 
Nonalcoholic cirrhos&s (42) 
Alcoholic cirrhosis (26) 
Cholestatic disease (28) 
Tumor (3) 
Fulminant failure (3) 
Miscellaneous (3) 
Children 
Sex (9 MI6 F) 
Biliary atresia (8) 
Cirrhosis (4) 
Tumor (2) 
Fulminant failure (1) 
Total 120 
Adapted from T odo el al.· 
pression have been described elsewhere. 10 This left 104 patients 
who have had continuous function of their original liver grafts for 
6 to 11.5 months. This subset was further reduced by eliminating 
three patients from analysis because they \10 ere on chronic dialysis 
at the time of liver transplantation. The clinical features of the 101 
patients included in the tinal analysis are summarized in Table 2. 
Eighty-eig.ht of these patients were adults and I3 were infants or 
children. 
Immunosuppression 
For the liver and heart recipients. IV doses of 0.075 mglkg or 0.15 
mglkg \Ioere infused over 4 hours in the operating room and 
repeated at a 0.075 mglkg dose every 12 hours until oral intake was 
started. The conversion from IV to oral do<,Cs of 0.15 mglkg every 
12 hours frequently overlapped for I day. The patients either were 
started on a 5-day burst of IV prednisone. starting at 200 mg on the 
tirst day and ending at 20 mg on the sixth day. or in many cases. 
the starting dose was 20 mg'd. If rejection occurred. the therapeu-
tic response was with an increase of FK 506 or steroids. or 
sometimes both. OKT3 was used in 10 (9.9'/(-) of the patients who 
had severe rejection. 
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FK 506 NEPHROTOXICITY 
Two recipients of double lungs and a heart-lung recipient were 
lreated differently in that no steroids or other drugs were added to 
FK 506 monotherapy. In these 3 patients_ FK 506 doses were 
itK:reased until there was evidence of renal dysfunction. Optimal 
use of FK 506 required surveillance of serum potassium, and if 
this increased, it was corrected with administration of tludrocorti-
sone acetate (Horinef), The usual starting doses offludrocortisone 
acetate were 0.1 mglbid, This therapy was initiated when serum 
potassium was >5,2-5.5 mEqlL. 
Hypertension was treated if the systolic and diastolic pressures 
consistently were over 160 and 90 mm Hg, respectively. Centrally 
acting agents (c\onidine) or calcium channel blockers were used 
preferentially. Beta blockers and ACE inhibitors that might exac-
erbate the hyperkalemia or block renal autoregulation generally 
were avoided, However, when these agents were used, no ad-
verse reactions were noted. 
Parameters Examined 
The serum creatinine and blood urea nitrogen were recorded 
preoperatively. Postoperatively, the mean results of these same 
lests were obtained for consecutive R-da~ postoperative periods 
for 30 days, at approximately 60 days, and at the last patient visit 
in July 1990 (5 to 10 months postoperativel~ L Plasma levels of FK 
~ were measured with the enzyme immunoassay technique of 
Tamura et aLII 
The incidence of arteria I hypertension was assessed by the need 
for antihypertensive drugs and by whether single or multiple 
agents were given. In addition, untreated patients whose diastolic 
blood pressures persistently were >95 mm Hg in absence of 
treatment were sought. None were found. 
Statistical Analyses 
Values for pooled data were expressed as mean :t SO. When 
appropriate, Student's I test or ANOVA were used to test the 
difference between means as appropriate. Values were considered 
to be significant when P < .05. 
RESULTS 
After Thoracic Organ Transplantation 
The evolution of the creatinine in the :!S heart recipients is 
shown in Fig I, Almost every recipient developed an 
increase in serum creatinine perioperatively. but these 
usually resolved by the end of the first postoperative 
month. One patient who had cardiac arrest and massage 
while on the way to the operating room required five 
hemodialysis treatments postoperatively_The periopera-
tive renal dysfunction was more pronounced in the eight 
02%) patients who were on assist de .. ices prior to trans-
plantation. Serum creatinine at latest foHow-up for all 
patients was 1,9 ::t: 0.6 mg/dL 
Twenty-two (88%) of the 25 heart recipients did not 
require any antihypertensive drugs. and the other 3 have 
mild hypertension and are (or were) 00 single agent ther-
apy, One of these three patients had a previous history of 
hypertension that persisted postoperatively. A second 
patient is taking verapamil for cardiac indications and had 
diastolic pressures of 90-96 mm Hg prior to therapy. 
Ten (40%) of the recipients were treated with fludro-
cortisone acetate at some time postopentively and 8 (32%) 
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Fig 1. Ser in heart transplants. Mean ± standard error lor heart 
transplant patients. Values from day 0 to 30 are expressed as 
mean :!: standard error at 5-day intervals. 
continue to require this agent at latest follow-up for control 
of hyperkalemia. 
The two double lung and the heart-lung recipients were 
managed solely with FK 506, In these patients. the FK 506 
dose was deliberately pushed to toxicity. Figure 2 shows 
the interrelations of FK 506 dose. plasma FK 506. and 
renal function over follow-ups of 5 to 9 months. Manage-
ment of the second double lung recipient was complicated 
by a cytomegalovirus (CMV) lung infestation and the need 
for intensive Gancyclovir therapy. He also was treated 
with Bactrim, Now after 8 to 10 months, the serum 
creatinine in the two double lung and heart-lung recipients 
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Fig 2. Ser it heart transplants. Individual clinical courses of a 
heart-lung and two double lung recipients who were treated with 
FK 506 only. 
--------~---.... -.--. 
1446 
is 1.9 ± 0.9 mg/dL. All are n •. Ilotensive without medica-
tion. 
Liver Transplantation 
Early renal dysfunction was also common in these liver 
recipients whose degree of nutritional and metabolic dis-
equilibrium was generally more severe than in the thoracic 
organ recipients. Nine (7.5%) of the patients required 
dialysis for the first time postoperatively. and in two cases. 
this was prolonged. Both cases were complicated postop-
eratively by recurrent hypotension and a need for nephro-
toxic antibiotics. For the remainder. the renal dysfunction 
was highly reversible. with downward adjustments of the 
FK 506 dosage. particularly if good liver function was 
obtained. Renal function was well preserved at latest 
follow-up with mean serum creatinine 1.4 ± 0.6 mg/dL 
(Fig 3). 
Eight-two (82%) of the 101 patients are normotensive. 
Sixteen of the 19 patients requiring treatment are receiving 
one agent and three require two agents at latest follow-up. 
Six of the patients requiring antihypertensive drug had a 
previous history of chronic hypertension. Two of these 
patients. both with 20-year histories of hypertension. re-
duced the number of antihypertensive drugs from 3 to 2 
after transplantation. An additional patient required nitro-
prusside acutely for blood pressure control prior to trans-
plantation. One of the patients developed hypertension 
when treated with dextroamphetamine sulfate (Dexadrine) 
for presumed narcolepsy. 
DISCUSSION 
In spite of the management complexity of thoracic organ 
and liver transplant recipients. a very clear picture of the 
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Fig 3. Serum creatinine in 101 primary liver transplant recipients. 
Values from day 0 to 30 are expressed as mean :t standard error 
at S-day intervals. 
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nephrotoxicity of FK 506 can be pieced together from 
these observations. At the drug doses used and within the 
context of these major operative interventions, early post-
operative dysfunction was a common. but usually not 
serious. factor in convalescence. With good function of the 
heart. lung. and liver grafts. it was possible to make 
downward adjustments of FK 506 dosage in response to 
increases in creatinine. and usually without countervailing 
increases of steroids or the addition of other agents such as 
azathioprine or antilymphoid preparations. Either with 
such adjustments or spontaneously. the creatinine could 
be expected to drift back to baseline. In the lung and 
heart-lung recipients who were kept steroid free, the highly 
reversible nephrotoxicity was used as a guide to establish 
the dose ceiling. Use of FK 506 in high doses frequently 
depended upon control of hyperkalemia with the min-
eralocorticoid. fludrocortisone acetate. even in patients 
with normal renal function. 
As has been noted beforeKPK9f~ the relative freedom 
from hypertension of patients on FK 506 was noteworthy. 
Until recently. the hypertension that has been associated 
with Cy A use was considered to be a nephrotoxic mani-
festation. However. there is evidence in animals '} and 
humans 14.15 that renal dysfunction and hypertension in-
duced by Cy A may be disassociated. If so. our finding of a 
low incidence of hypertension is less surprising. The 
contribution of prior history of hypertension undoubtedly 
predisposes these patients to hypertension after transplan-
tation. 
Detailed further studies are needed to study the influ-
ence of FK 506 on renal function. and the mechanisms of 
this influence. During the last year. it has been learned that 
the FK 506 cytosolic binding site. while distinct from the 
binding site of CyA (cyclophilinl. has in common with 
cyclophilin a high constituency of the enzyme peptidyl-
prolyl isomerase (PPIase).16.17 This enzyme. which is 
presumably inhibited as the central immunosuppressive 
action of both drugs. is heavily represented in the kidney 
and was actually discovered there. 18 Since PPIase is 
ubiquitously distributed throughout virtually all tissues. its 
inhibition by these immunosuppressive drugs will have 
mUltiple ramifications. For example. the hyperkalemia that 
is mineralocorticoid responsive is thought to be due to a 
selective deficiency of aldosterone and renin. This could 
have its origin in the adrenal gland or the juxtaglomerular 
apparatus in the kidneys. 
In prospective studies of the effect of FK 506 on renal 
function. patients with non hepatic autoimmune diseases 
should provide the most reliable information since the 
artefacts caused by major surgical intervention will be 
eliminated. Such studies (it will be important to know the 
status of the liver studies presented elsewhere at this 
meeting) have shown how remartably the pharmacokinet-
ics (the absorption. bioavailability. and elimination) of FK 
506 are altered by liver function. and how different these 
FK 506 NEPHROTOXICllY 
alterations are from those seen with CyA under similar 
circumstances. With either drug, studying renal function 
under the swiftly changing hepatic dynamics of liver trans-
plantation will require more sophisticated pharmacologic 
monitoring than has been previously used. 
We reported earlier that most patients who switched 
from CyA to FK 506 had significant increases in serum 
creatinine. and we concluded that these two agents were 
synergistically nephrotoxic. I •2 Further documentation of 
this phenomenon has been presented at this meeting. 19 In 
an ischemic rat model, Nalesnik et al5 have shown that FK 
506 causes some of the same changes as CyA including 
tabular vacuolization, but to a lesser degree. 
. rrl-le 0l--tC 
SUMMARY f'\ Q.l(.\ \! \ -Q '\ eJ elL ~ 1'hfl'j:, f \ d~ ': 
Formal studies have not been published on the nephrotox-
icity of FK 506 when the drug was used from the outset. 
This kind of information was sought in 101 recipients of 
primary livers. 24 hearts, and 3 double lungs or heart-lung. 
Perioperative renal dysfunction was commonly seen, 
which appeared to be related to FK 506 doses and plasma 
levels, particularly when the drug was given IV. This was 
reversible. Late renal function has been generally satisfac-
tory in all three cohorts of patients, and the incidence of 
hypertension has been low. The therapeutic index of FK 
506 is a good one, as revealed by these observations in 
patients whose most notable achievement was a low 
mortality. . !J Ar~t~· FfD~~y ~ ''"'t. --L ~ D. o~~ \ ~ ~ 00_\(1 "-I 
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